Quadazocine

Quadazocine
Clinical data
ATC code	None;
Identifiers
	IUPAC name 1-cyclopentyl-5-[(1S,9R)-4-hydroxy-1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2,4,6-trien-13-yl]-3-pentanone;
CAS Number	71276-43-2 ;
PubChem CID	115077;
ChemSpider	102983;
UNII	X9BMD58553;
CompTox Dashboard (EPA)	DTXSID30990187 ;
Chemical and physical data
Formula	C25H37NO2
Molar mass	383.576 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(CCC1CCCC1)CCC4([C@@H]3N(CC[C@]4(c2c(ccc(O)c2)C3)C)C)C;
	InChI InChI=1S/C25H37NO2/c1-24-14-15-26(3)23(16-19-9-11-21(28)17-22(19)24)25(24,2)13-12-20(27)10-8-18-6-4-5-7-18/h9,11,17-18,23,28H,4-8,10,12-16H2,1-3H3/t23-,24+,25?/m1/s1; Key:LOYWOYCPSWPKFH-CSIQULDISA-N;

Quadazocine (WIN-44,441) is an opioid antagonist of the benzomorphan family which is used in scientific research.^[1] It acts as a silent antagonist at all three of the major opioid receptors—μ, κ, and δ,^[1]^[2] but with a significant preference in affinity for the μ receptor and the κ₂ subtype.^[3]^[4]^[5] As such, it has been touted as a "κ₂-selective" antagonist, though this is not entirely accurate on account of its similar affinity for the μ receptor.^[3]^[5] As would be expected, quadazocine reverses the effects (e.g., analgesia) of opioid agonists like morphine and fentanyl in animals.^[1]^[6]